Literature DB >> 35435445

Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology-Rheumatology clinic: a retrospective real-world study.

Kalliopi Klavdianou1, Maria Stavropoulou2, Pantelis Panagakis3, Marina Papoutsaki4, Alexandros Panagiotopoulos1, Christos Koutsianas1, Alexandros Stratigos4, Dimitrios Rigopoulos4, Dimitrios Vassilopoulos5.   

Abstract

The aim of this study was to assess the patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis (PsA) referred to a combined Dermatology-Rheumatology (Derm-Rheum) Clinic. This was a retrospective study of patients seen in a combined Derm-Rheum Clinic (February 2018 to June 2020) in a Tertiary University Hospital. Consecutive patients with suspicious musculoskeletal symptoms or a known diagnosis of PsA referred to the Derm-Rheum Clinic were examined and followed simultaneously by experienced dermatologists and rheumatologists. Among 151 patients with psoriasis (PSO) with suspicious musculoskeletal complaints, 129 (85%) with a final diagnosis of PsA were included (56% females, mean age: 55 years, median disease duration: 14.2 years). In 62% of these patients (n = 94), PsA was diagnosed for the 1st time. At initial evaluation, 95% had peripheral arthritis, 45% nail involvement, 23% axial involvement, 12% enthesitis and 6% dactylitis with a median DAPSA and PASI scores of 20.5 and 1.6, respectively. 31% of the patients were not receiving any systemic treatment, 45% were on biologics, 29% on non-biologics and 10% on targeted synthetic agents (apremilast). At last visit (median interval time: 15 months), only 8% did not receive any systemic therapy (p < 0.001 compared to 1st visit), 62% were on biologics (p = 0.009 compared to 1st visit), 46% on non-biologics (p = 0.01 compared to 1st visit) and 10% remained on apremilast. The median DAPSA and PASI scores decreased significantly to 5.3 and 0, respectively. In conclusion, about 2/3 of patients with PSO and musculoskeletal complaints referred to a combined Derm-Rheum Clinic were diagnosed for the 1st time with PsA. During follow-up, the percentage of PsA patients on systemic therapies significantly increased with major improvement of disease activity indices. These data emphasize the value of combined Derm-Rheum Clinics for earlier referral, diagnosis, and more effective treatment of PsA patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Interdisciplinary health team; Psoriasis; Psoriatic arthritis; Spondyloarthritis

Mesh:

Substances:

Year:  2022        PMID: 35435445     DOI: 10.1007/s00296-022-05126-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

Review 1.  The Epidemiology of Psoriatic Arthritis.

Authors:  Alexis Ogdie; Pamela Weiss
Journal:  Rheum Dis Clin North Am       Date:  2015-09-11       Impact factor: 2.670

Review 2.  Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.

Authors:  Jose U Scher; Alexis Ogdie; Joseph F Merola; Christopher Ritchlin
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

3.  Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis.

Authors:  William Tillett; Deepak Jadon; Gavin Shaddick; Charlotte Cavill; Eleanor Korendowych; Corinne S de Vries; Neil McHugh
Journal:  Ann Rheum Dis       Date:  2013-01-03       Impact factor: 19.103

Review 4.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Authors:  Craig A Elmets; Craig L Leonardi; Dawn M R Davis; Joel M Gelfand; Jason Lichten; Nehal N Mehta; April W Armstrong; Cody Connor; Kelly M Cordoro; Boni E Elewski; Kenneth B Gordon; Alice B Gottlieb; Daniel H Kaplan; Arthur Kavanaugh; Dario Kivelevitch; Matthew Kiselica; Neil J Korman; Daniela Kroshinsky; Mark Lebwohl; Henry W Lim; Amy S Paller; Sylvia L Parra; Arun L Pathy; Elizabeth Farley Prater; Reena Rupani; Michael Siegel; Benjamin Stoff; Bruce E Strober; Emily B Wong; Jashin J Wu; Vidhya Hariharan; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2019-02-13       Impact factor: 11.527

5.  Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?

Authors:  Dafna D Gladman; Arane Thavaneswaran; Vinod Chandran; Richard J Cook
Journal:  Ann Rheum Dis       Date:  2011-09-12       Impact factor: 19.103

6.  Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic.

Authors:  Nicole F Velez; Erin X Wei-Passanese; M Elaine Husni; Elinor A Mody; Abrar A Qureshi
Journal:  Arch Dermatol Res       Date:  2012-01       Impact factor: 3.017

7.  Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.

Authors:  Muhammad Haroon; Phil Gallagher; Oliver FitzGerald
Journal:  Ann Rheum Dis       Date:  2014-02-13       Impact factor: 19.103

8.  Psoriatic arthritis (PSA)--an analysis of 220 patients.

Authors:  D D Gladman; R Shuckett; M L Russell; J C Thorne; R K Schachter
Journal:  Q J Med       Date:  1987-02

9.  Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study.

Authors:  E Papadavid; P Katsimbri; I Kapniari; D Koumaki; A Karamparpa; M Dalamaga; K Tzannis; D Βoumpas; D Rigopoulos
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-08-10       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.